絞り込み

16645

広告

Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention.

著者 Oyagüez I , Suárez C , López-Sendón JL , González-Juanatey JR , de Andrés-Nogales F , Suárez J , Polanco C , Soto J
Pharmacoecon Open.2019 Oct 31 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (50view , 0users)

Full Text Sources

Miscellaneous

Our objective was to assess the cost effectiveness of apixaban versus edoxaban in the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) in Spain.
PMID: 31673882 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード